{"filings":[{"id":778917,"accession_number":"0001193125-26-251548","cik":1609809,"company_name":"Seres Therapeutics, Inc.","ticker":"MCRB","form_type":"8-K","filed_at":"2026-06-01T20:30:55+00:00","items":["5.02"],"status":"ready","headline":"Seres Therapeutics board member Hans-Juergen Woerle resigns, effective May 31, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Woerle resigned from the board and all committees, effective May 31, 2026.","Departure is not due to any disagreement with Seres' operations, policies, or practices.","No replacement or additional board changes were announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":74178930.00262123,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94074,"accession_number":"0001193125-26-205009","cik":1609809,"company_name":"Seres Therapeutics, Inc.","ticker":"MCRB","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Seres Q1 2026 net loss $19.9M; cash runway only through Q3 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $19.9M vs net income $32.7M in Q1 2025 (which included $50M Nestlé payment).","Cash and equivalents $29.8M as of March 31, 2026; expects to fund ops only through Q3 2026.","R&D expenses $13.2M (up from $11.8M), G&A $8.1M (down from $11.9M); no manufacturing services expenses.","SER-155 IST for immune checkpoint inhibitor-related enterocolitis enrollment complete (15 pts); data expected in coming weeks.","SER-155 Phase 2 ready for allo-HSCT but seeking funding; SER-603 preclinical for IBD with IND-enabling activities ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":358000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":74178930.00262123,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106181,"accession_number":"0001193125-26-108482","cik":1609809,"company_name":"Seres Therapeutics, Inc.","ticker":"MCRB","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Seres Therapeutics sets 2026 annual meeting for June 9","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Record date for voting is April 13, 2026; stockholders of record on that date are entitled to vote.","Rule 14a-8 stockholder proposals must be received by March 26, 2026, which is 10 days after this filing.","Definitive proxy statement will specify meeting time and location.","Meeting is scheduled more than 30 days after the 2025 annual meeting, triggering the revised proposal deadline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":74178930.00262123,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106180,"accession_number":"0001193125-26-103034","cik":1609809,"company_name":"Seres Therapeutics, Inc.","ticker":"MCRB","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Seres Therapeutics reports FY 2025 net income of $5.7M from continuing ops; cash runway through Q3 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year 2025 net income from continuing ops $5.7M vs net loss of $125.8M in 2024; Q4 net loss $15.3M.","Cash and equivalents $45.8M as of Dec 31, 2025; expects to fund operations through Q3 2026.","SER-155 IST for immune checkpoint-related enterocolitis fully enrolled; data expected Q2 2026.","SER-603 for IBD in IND-enabling activities; seeking partnerships for clinical advancement.","Richard Kender appointed Executive Chair and interim CEO; company prioritized inflammatory/immune programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":74178930.00262123,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106179,"accession_number":"0001193125-26-085368","cik":1609809,"company_name":"Seres Therapeutics, Inc.","ticker":"MCRB","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Seres Therapeutics appoints Richard Kender as Interim CEO, effective March 2","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Thomas DesRosier and Marella Thorell step down as co-Presidents/co-CEOs but remain EVP CLO and EVP CFO.","Kender receives $520K base salary, $250K signing bonus, and options for 200,000 shares.","Matthew Henn named President (in addition to CSO); salary increased to $505K, $230K retention bonus.","Kelly Brady promoted to EVP COO; salary $475K, $230K retention bonus, options for 75,000 shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":74178930.00262123,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122461,"accession_number":"0001193125-25-265708","cik":1609809,"company_name":"Seres Therapeutics, Inc.","ticker":"MCRB","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Seres Q3 net income $8.2M on VOWST gain; cash runway through Q2 2026; SER-155 Phase 2 protocol finalized pending funding","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income from continuing ops $8.2M vs loss of $51.0M in Q3 2024, driven by $27.2M gain on VOWST sale.","Cash and equivalents $47.6M; expects to fund operations only through Q2 2026, noting ongoing capital needs.","FDA feedback received; SER-155 Phase 2 protocol for BSI prevention in allo-HSCT being finalized, pending study funding.","CARB-X grant of up to $3.6M awarded for oral liquid formulation of SER-155; IST in irEC initial results expected early 2026.","Cost-reduction measures implemented including workforce decrease; R&D expense $12.6M, G&A $9.5M in Q3."],"consensus_eps_estimate":null,"consensus_eps_actual":2.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":351000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":74178930.00262123,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":122460,"accession_number":"0001193125-25-230118","cik":1609809,"company_name":"Seres Therapeutics, Inc.","ticker":"MCRB","form_type":"8-K","filed_at":"2025-10-03T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Seres Therapeutics cuts workforce 25%, extends cash runway into Q2 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reducing workforce by approximately 25%, including reductions effective August 2025.","Expected cash charges of $1.0-1.4 million, primarily severance, paid in Q4 2025.","Cash runway extended into Q2 2026 based on current operating plans and cost savings.","Company cites need to reduce costs to advance strategic priorities amid ongoing losses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":74178930.00262123,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139156,"accession_number":"0001193125-25-173985","cik":1609809,"company_name":"Seres Therapeutics, Inc.","ticker":"MCRB","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Seres Q2 net loss narrows to $19.9M; CEO replaced; SER-155 Phase 2 protocol filed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss from continuing ops $19.9M in Q2 2025 vs $26.2M in Q2 2024; cash $45.4M as of June 30.","Received $25M Nestlé installment in July; expects cash runway into Q1 2026.","Co-CEOs Thomas DesRosier and Marella Thorell appointed Aug 1 after prior CEO Eric Shaff departed.","SER-155 Phase 2 protocol submitted to FDA for BSI prevention in allo-HSCT; awaiting FDA feedback.","Engaging with multiple parties on partnerships, out-licensing, or mergers to secure capital."],"consensus_eps_estimate":null,"consensus_eps_actual":1.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":74178930.00262123,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139155,"accession_number":"0001193125-25-162552","cik":1609809,"company_name":"Seres Therapeutics, Inc.","ticker":"MCRB","form_type":"8-K","filed_at":"2025-07-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Seres Therapeutics CEO Eric Shaff resigns; CFO and CLO appointed as Co-CEOs effective Aug 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Eric Shaff resigns as President and CEO effective July 31, 2025; remains on Board as Class I director.","Marella Thorell (EVP/CFO) and Thomas DesRosier (EVP/CLO) appointed Co-CEOs and Co-Presidents effective Aug 1, 2025.","Shaff to receive prorated 2025 bonus; Board may accelerate payment if a strategic transaction closes before year-end.","Thorell and DesRosier each receive $500,000 appointment bonus: one-third on Aug 1, 2025, balance on Jan 1, 2026 subject to retention."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":74178930.00262123,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156698,"accession_number":"0001193125-25-114430","cik":1609809,"company_name":"Seres Therapeutics, Inc.","ticker":"MCRB","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Seres Q1 net income $32.7M; SER-155 Phase 2 protocol to FDA in weeks","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net income from continuing ops of $32.7M vs net loss of $32.9M YoY, driven by $50M Nestlé installment.","R&D expense down to $11.8M from $19.5M; G&A down to $11.9M from $14.9M.","Cash $58.8M at Mar 31, plus $25M Nestlé installment expected July 2025; runway into Q1 2026.","Plans SER-155 Phase 2 study (248 patients, adaptive design) with interim analysis within 12 months of start.","Regained Nasdaq compliance after 1-for-20 reverse stock split on April 21, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":74178930.00262123,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156697,"accession_number":"0001193125-25-089189","cik":1609809,"company_name":"Seres Therapeutics, Inc.","ticker":"MCRB","form_type":"8-K","filed_at":"2025-04-22T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Seres Therapeutics effects 1-for-20 reverse stock split, effective April 21, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-20 ratio, effective 5:00 PM ET on April 21, 2025.","Common stock begins split-adjusted trading on Nasdaq on April 22, 2025 under symbol MCRB.","No fractional shares will be issued; holders receive cash in lieu of fractional shares.","Authorized shares and par value per share remain unchanged.","Stockholders approved split range of 1:5 to 1:50; Board fixed final ratio at 1:20."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":74178930.00262123,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156696,"accession_number":"0001193125-25-080185","cik":1609809,"company_name":"Seres Therapeutics, Inc.","ticker":"MCRB","form_type":"8-K","filed_at":"2025-04-14T23:59:59+00:00","items":["5.02","5.07","8.01","9.01"],"status":"ready","headline":"Seres Therapeutics stockholders approve 1-for-20 reverse stock split, 2025 Incentive Plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split at 1-for-20 ratio approved; effective April 21, 2025; trading on split-adjusted basis April 22 under symbol MCRB.","2025 Incentive Award Plan authorized 44,604,870 shares for future awards, amending and restating the 2015 Plan.","Three Class I directors elected: Dennis A. Ausiello, M.D.; Willard H. Dere, M.D.; Eric D. Shaff.","Advisory say-on-pay vote passed with 57.9M for vs 32.5M against.","Proposals to amend certificate to eliminate supermajority voting and clarify share authorization did not pass."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":74178930.00262123,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175111,"accession_number":"0001193125-25-053473","cik":1609809,"company_name":"Seres Therapeutics, Inc.","ticker":"MCRB","form_type":"8-K","filed_at":"2025-03-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Seres Q4 net loss from continuing ops $15.7M; cash extends into Q1 2026; SER-155 advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss from continuing ops: FY2024 $125.8M vs $190.1M in 2023; Q4 $15.7M vs $34.7M.","R&D expenses fell to $64.6M (FY2024) from $117.6M; focus on lead program SER-155.","Cash $30.8M at Dec 31; plus $50M received Jan 2025, expects funding into Q1 2026.","SER-155: FDA supports BSI reduction at day 30 as Phase 2 endpoint; draft protocol in Q2 2025.","Expecting $25M Nestlé installment in July 2025; VOWST sale yields up to $275M in milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":74178930.00262123,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175110,"accession_number":"0001193125-25-039256","cik":1609809,"company_name":"Seres Therapeutics, Inc.","ticker":"MCRB","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Seres Therapeutics CMO Lisa von Moltke resigns effective March 14, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lisa von Moltke, M.D., notified Seres of her resignation as EVP and Chief Medical Officer.","Resignation effective March 14, 2025; she accepted a CMO and Head of R&D role at a biopharma.","No successor named; search process not disclosed.","Dr. von Moltke's departure is for a role in autoimmune disease therapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":74178930.00262123,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175109,"accession_number":"0001193125-25-021345","cik":1609809,"company_name":"Seres Therapeutics, Inc.","ticker":"MCRB","form_type":"8-K","filed_at":"2025-02-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Seres Therapeutics appoints Hans-Juergen Woerle, M.D. to board, designated by Nestlé","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded to nine directors; Woerle appointed as Class III director effective Feb 4, 2025.","Woerle is Chief Medical Officer and Chief Scientific Officer at Nestlé Health Science since Nov 2018.","Designated by Nestlé under Securities Purchase Agreement requiring Nestlé to hold ≥10% of shares.","Initial option grant of 120k shares at $0.8056 strike, vesting over 4 years; annual retainer $45k plus $7.5k for committee service.","Woerle also serves on Enterome SA board and previously Cerecin Inc. board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":74178930.00262123,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175108,"accession_number":"0001193125-25-005011","cik":1609809,"company_name":"Seres Therapeutics, Inc.","ticker":"MCRB","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Seres Therapeutics posts updated corporate presentation for JPMorgan conference without new material data","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company posted updated corporate presentation on investor website ahead of J.P. Morgan Conference on January 16, 2025.","Presentation contains no new financial guidance, clinical data, or material operational milestones.","No material changes from previously disclosed results or pipeline status are indicated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":74178930.00262123,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175107,"accession_number":"0001193125-25-004062","cik":1609809,"company_name":"Seres Therapeutics, Inc.","ticker":"MCRB","form_type":"8-K","filed_at":"2025-01-10T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Seres reports $31M cash, SER-155 biomarker data positive, FDA Breakthrough Therapy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Prelim cash $31M as of Dec 31, 2024; with Nestlé payments of ~$75M, cash runway into Q1 2026.","SER-155 Phase 1b biomarker: significant decrease in fecal albumin (epithelial barrier integrity) vs placebo.","FDA granted Breakthrough Therapy designation for SER-155 in allo-HSCT in Dec 2024.","Briefing Book submitted for next registrational study; FDA feedback expected Q1 2025.","SER-155 results accepted for oral presentation at TANDEM Meeting Feb 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":74178930.00262123,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192056,"accession_number":"0001193125-24-256654","cik":1609809,"company_name":"Seres Therapeutics, Inc.","ticker":"MCRB","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","3.01","7.01","9.01"],"status":"ready","headline":"Seres receives Nasdaq bid-price deficiency notice; Q3 net loss $51M from cont. ops; SER-155 shows 77% BSI reduction","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Seres (MCRB) that bid price closed below $1.00 for 30 consecutive business days; must regain compliance by May 6, 2025.","Q3 2024 net loss from continuing ops $51M (vs $41M in Q3 2023); R&D exp $16.5M, G&A $12.7M.","SER-155 Phase 1b: 77% relative risk reduction in bloodstream infections, lower antibiotic use & febrile neutropenia vs placebo; Breakthrough Therapy requested.","VOWST sale closed Sep 2024 for ~$175M gross proceeds; expects $50M in Jan 2025 and $25M in Jul 2025; no debt outstanding.","Cash $66.8M as of Sep 30; expects to fund into Q4 2025 with existing cash and installment payments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":74178930.00262123,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192055,"accession_number":"0001193125-24-230144","cik":1609809,"company_name":"Seres Therapeutics, Inc.","ticker":"MCRB","form_type":"8-K","filed_at":"2024-10-01T23:59:59+00:00","items":["1.01","1.02","2.01","3.02","7.01","9.01"],"status":"ready","headline":"Seres completes VOWST sale to Nestlé for ~$175M gross; debt retired, runway to Q4 2025","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Received ~$175M gross at close: $100M upfront, $60M prepaid milestone, $15M equity; net ~$155M after ~$20M settlement.","Repaid $128M to Oaktree, terminating $110M term loan; debt fully retired.","Expects $50M installment in Jan 2025, $25M in July 2025; up to $275M future milestones tied to VOWST sales.","Focus shifts to SER-155 (promising Phase 1b allo-HSCT data), SER-147; headcount cut from ~200 to ~100.","Cash runway extended into Q4 2025; plans to seek Breakthrough Therapy designation for SER-155."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":74178930.00262123,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208543,"accession_number":"0001193125-24-226929","cik":1609809,"company_name":"Seres Therapeutics, Inc.","ticker":"MCRB","form_type":"8-K","filed_at":"2024-09-26T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Seres stockholders approve sale of VOWST business to Nestlé; close expected Sept 30","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Stockholders voted 77.1M for, 7.1M against, and 0.2M abstain to approve the sale of VOWST business to Société des Produits Nestlé S.A.","Non-binding advisory compensation proposal for named executives also passed (63.1M for, 20.9M against, 0.4M abstain).","Transaction expected to close on September 30, 2024, subject to customary closing conditions.","VOWST is a microbiome therapeutic; the sale was originally announced under an asset purchase agreement dated August 5, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":74178930.00262123,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208542,"accession_number":"0001193125-24-217627","cik":1609809,"company_name":"Seres Therapeutics, Inc.","ticker":"MCRB","form_type":"8-K","filed_at":"2024-09-12T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Seres' SER-155 reduces BSIs 10% vs 42.9% in allo-HSCT Phase 1b; seeks Breakthrough Therapy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["SER-155 cut bloodstream infections to 10% vs 42.9% placebo (p=0.0423) in 34 evaluable patients.","Antibiotic exposure duration significantly shorter: 9.2 days vs 21.1 days (p=0.0494).","Febrile neutropenia incidence 65% vs 78.6% (not statistically significant).","No treatment-related serious adverse events; drug strains engrafted in GI tract.","Plans to seek FDA Breakthrough Therapy designation and discuss next steps for allo-HSCT."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":74178930.00262123,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208541,"accession_number":"0001140361-24-037388","cik":1609809,"company_name":"Seres Therapeutics, Inc.","ticker":"MCRB","form_type":"8-K","filed_at":"2024-08-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Seres files prior financials for proxy on VOWST asset sale; auditor flags going concern","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Furnishes 2022-2023 audited financial statements for incorporation in proxy statement related to sale of VOWST microbiome assets.","Auditor notes substantial doubt about ability to continue as going concern due to recurring losses and negative cash flows.","Financial statements consistent with prior Form 10-K filed March 5, 2024; no updates for subsequent events."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":74178930.00262123,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208540,"accession_number":"0001193125-24-199382","cik":1609809,"company_name":"Seres Therapeutics, Inc.","ticker":"MCRB","form_type":"8-K","filed_at":"2024-08-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Seres Q2 net loss $32.9M; VOWST sales $14.4M (+43% QoQ); announces $175M asset sale to Nestlé","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $32.9M vs net income $46.6M in Q2 2023 (prior year included $125M VOWST milestone from Nestlé).","VOWST Q2 net sales $14.4M, up 43% sequentially; Seres share of profit/loss was a $6.6M net loss.","VOWST asset sale to SPN (Nestlé) provides $175M cash less ~$20M settlement; proceeds to retire Oaktree debt.","SER-155 Phase 1b Cohort 2 placebo-controlled readout on track for September; SER-147 IND readiness H2 2025.","Cash $71.2M at June 30; with deal proceeds expects runway into Q4 2025; without deal into Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":74178930.00262123,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208539,"accession_number":"0001140361-24-035951","cik":1609809,"company_name":"Seres Therapeutics, Inc.","ticker":"MCRB","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["1.01","1.02","3.02","9.01"],"status":"ready","headline":"Seres sells VOWST business to Nestlé for up to $100M cash plus milestones; issues $15M stock","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Cash payment of $100M at closing (net of ~$17.9M owed to Nestlé affiliate and ~CHF2M to Bacthera); $50M due Jan 2025, $25M July 2025.","Prepaid $60M milestone for $150M annual net sales; future milestones of $125M at $400M and $150M at $750M in sales.","Seres and Nestlé share 50/50 net profit/loss on VOWST in 2025 profit-sharing period.","Nestlé to purchase 14,285,715 shares at $1.05/share ($15M); Seres to register resale within 90 days.","Post-closing Seres to focus on SER-155 and other biotherapeutic candidates; stockholder vote required."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":74178930.00262123,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":208538,"accession_number":"0001140361-24-035799","cik":1609809,"company_name":"Seres Therapeutics, Inc.","ticker":"MCRB","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Seres sells VOWST to Nestlé Health Science for $175M upfront plus milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Seres to receive $175M at closing: $100M upfront (less ~$20M net settlement), $60M prepaid milestone, $15M equity at $1.05/share.","Additional $75M due in 2025 subject to transition obligations; up to $275M in future commercial milestones on VOWST net sales.","Seres to fully retire its senior secured debt with Oaktree at closing; expects cash runway into Q4 2025.","Workforce to be reduced by more than one-third as VOWST capabilities transfer to Nestlé.","Pipeline focus shifts to SER-155; Phase 1b placebo-controlled Cohort 2 data expected September 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":74178930.00262123,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}